ArticleThe Journal of dermatology2025
Treatment Persistence After Major Cardiovascular Events in Psoriasis: A Retrospective Cohort Study Comparing Biologic, Systemic, and Phototherapy.
Article in The Journal of dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Patients with psoriasis experience significantly higher cardiovascular morbidity compared to the general population. Although certain psoriasis treatments may confer cardioprotective effects, current clinical guidelines addressing treatment continuation following major adverse cardiovascular events (MACE) are lacking. Therefore, we conducted a retrospective cohort study using Korean health insurance data (January 2008-October 2021) to examine treatment modifications after MACE in patients with psoriasis. Patients were categorized based on treatment type: biologics, non-biologic systemic agents (cyclosporine or methotrexate), and phototherapy. Treatment persistence within 3 months after MACE was assessed using multivariable logistic regression, adjusted for demographic and clinical factors. Subgroup analyses were conducted based on previous MACE history. This retrospective cohort study included 1012 patients with MACE history and 2981 without. Biologic therapies demonstrated significantly superior treatment persistence (79.7%) compared to non-biologic systemic therapies (46.9%) and phototherapy (47.0%). Switching therapies was uncommon across all treatment groups (0.8%-1.9%). Multivariable logistic regression analysis confirmed that biologics were associated with greater treatment persistence than cyclosporine (odds ratio [OR], 4.854; 95% confidence interval [CI], 2.476-9.516), methotrexate (OR, 3.616; 95% CI, 1.760-7.431), and phototherapy (OR, 4.556; 95% CI, 2.340-8.873). These findings remained consistent in both the new-onset and recurrent MACE subgroups. No significant difference in treatment persistence was observed between the non-biologic systemic therapy and phototherapy groups. In conclusion, patients receiving biologic therapies were more likely to continue treatment after a cardiovascular event compared to those receiving other therapies. These findings suggest that biologics are perceived as safer options in this high-risk population and underscore the need for clear, evidence-based guidance on psoriasis treatment following cardiovascular events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.